News

Focus on Progena - Swiss foundation for children with DMD and other rare genetic diseases

As part of our series featuring TREAT-NMD members, this week we feature information about the Swiss organisation Progena.

Progena was founded in 2006 by the parents of a Duchenne boy. When they had to come to terms with their son's diagnosis, they didn’t find much help from existing infrastructures, whether public or private. They thus decided to create a foundation to raise funds for research into rare genetic diseases in children and help and support the families of affected children.

Progena also tries to collaborate with the various associations in Switzerland, in order to concentrate the efforts and aim into a common direction. This is not an easy task, as Switzerland is divided into 4 different language regions, with as many different ways of approach.

Progena's aim is to unite the interests of all affected individuals and to create a professional and efficient structure in terms of fundraising and support to families. Since 2008, Progena has been working in a close relationship with the Swiss Telethon, which raises more than 2 million Swiss Francs each year, just before Christmas. However, Progena wishes to extend fundraising to medium sized and large corporations in order to obtain sustainable funding over the whole year and not only at one specific period.

Progena Image


The local commitments of Progena...



Parents of children who suffer from rare genetic diseases undergo huge changes in their everyday lives. They often need help with challenges such as integration at school, logopedics, ergotherapy, physiotherapy, auxiliary means, nutrition, and adapting the household. To help parents find answers, support and especially understanding about all these issues, Progena started meeting evenings in 2008 for parents who have children who suffer from neuromuscular diseases.  These evenings serve as a forum where parents can meet and talk with other parents. Occasionally, specialist speakers (scientists, doctors, social workers...) are invited to share views with the parents. 3 to 4 meetings are organised each year and are considered very successful. Progena also runs a website where the latest information is published and updated regularly: www.progena.ch

...and the international commitments


Due to the character and rare incidence of these diseases, it is absolutely essential to join forces and act across borders to find a common solution to fight and eventually treat these diseases. Progena represents Switzerland within larger associations and organizations in Europe. Progena is hence a member of UPPMD – United Parent Project Muscular Dystrophy – which brings together national organisations of parents with children suffering from DMD.  Progena is also member of TREAT-NMD, a network created and financed by the European Commission in 2007. Its main objective is to establish therapeutic treatments and to accelerate the availability of treatments for patients suffering from neuromuscular diseases. Progena is also supporting TREAT-NMD by translating brochures into French for the benefit of French speakers worldwide.

Projects  
 

Clinical trials for rare genetic diseases are currently being set up both in Europe and the US. Through national registries, each country needs to ensure the participation of patients who could potentially benefit. In 2008, a national registry for patients suffering from SMA and DMD/BMD was established in Switzerland under the supervision of Doctor Pierre-Yves Jeannet, Neurological Pediatrician at CHUV in Lausanne, and Doctor Andrea Klein, Neurological Pediatrician at the Children’s Hospital in Zurich. From the outset, Progena has contributed financially to the Swiss Patient Registry project, ensuring that Swiss patients participate in these crucial clinical trials in Europe and elsewhere. Progena not only finances this type of project but also raises awareness in order to access public funds. New projects are coming along in 2010 and are currently under evaluation.

Committee:
Robert Palm, President
r.palm@progena.ch
079 211 24 18
Huguette Palm, Secretary
h.palm@progena.ch
079 632 46 46

Address:
Rue du Temple 7
Case postale 45
1180 Rolle, Switzerland
contact@progena.ch
www.progena.ch



 

 


TREAT-NMD Coordination Office: T: +44 191 241 8605 Fax: +44 191 241 8770 E:
FP6 Logo TREAT-NMD is supported through Priority 1 (Life Sciences, Genomics and Biotechnology for Health) of the European Union’s FP6 under contract number LSHM-CT-2006-036825 EU flag